tbuckley/cabot-search huggingface dataset:
CMS: New Rule Will Improve Efficiency and Speed of Prior Authorization
Authors: Emily Harris
Journal: JAMA (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prevalence of Pretreatment Testing Recommended for Patients With Chronic Inflammatory Skin Diseases
Authors: Maria C. Schneeweiss, Denys Shay, Sophia Ly, Richard Wyss, Sebastian Schneeweiss, Robert J. Glynn, Arash Mostaghimi
Journal: JAMA Dermatology (2024)

Laboratory testing for the presence of tuberculosis, hepatitis, and other conditions before starting most systemic immunomodulatory agents is recommended in patients with chronic inflammatory skin diseases (CISD) but current testing patterns in the US are unclear.
Perspectives on Full-Body Skin Examinations Among Sexual and Gender Minority Patients
Authors: Michelle Verghese, Jincong Q. Freeman, Brian W. Connor, Aniruddha Hazra, Andrew R. Fisher, Adena E. Rosenblatt
Journal: JAMA Dermatology (2024)

This survey study assesses full-body skin examination rates among sexual and gender minority patients and investigates their comfort with and reasons for discomfort during these examinations.
Missed Vaccine Doses Tied to Worse COVID-19 Outcomes
Authors: Emily Harris
Journal: JAMA (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Authors: Audrey Lumeau, Nicolas Bery, Audrey Francès, Marion Gayral, Guillaume Labrousse, Cyril Ribeyre, Charlene Lopez, Adele Nevot, Abdessamad El Kaoutari, Naima Hanoun, Emeline Sarot, Marion Perrier, Frederic Pont, Juan-Pablo Cerapio, Jean-Jacques Fournié, Frederic Lopez, Miguel Madrid-Mencia, Vera Pancaldi, Marie-Jeanne Pillaire, Valerie Bergoglio, Jerome Torrisani, Nelson Dusetti, Jean-Sebastien Hoffmann, Louis Buscail, Malik Lutzmann, Pierre Cordelier
Journal: Cancer Research (2024)

Abstract Cytidine deaminase (CDA) functions in the pyrimidine salvage pathway for DNA and RNA syntheses and has been shown to protect cancer cells from deoxycytidine-based chemotherapies. In this study, we observed that CDA was overexpressed in pancreatic adenocarcinoma from patients at baseline and was essential for experimental tumor growth. Mechanistic investigations revealed that CDA localized to replication forks where it increased replication speed, improved replication fork restart efficiency, reduced endogenous replication stress, minimized DNA breaks, and regulated genetic stability during DNA replication. In cellular pancreatic cancer models, high CDA expression correlated with resistance to DNA-damaging agents. Silencing CDA in patient-derived primary cultures in vitro and in orthotopic xenografts in vivo increased replication stress and sensitized pancreatic adenocarcinoma cells to oxaliplatin. This study sheds light on the role of CDA in pancreatic adenocarcinoma, offering insights into how this tumor type modulates replication stress. These findings suggest that CDA expression could potentially predict therapeutic efficacy and that targeting CDA induces intolerable levels of replication stress in cancer cells, particularly when combined with DNA-targeted therapies. Significance: Cytidine deaminase reduces replication stress and regulates DNA replication to confer resistance to DNA-damaging drugs in pancreatic cancer, unveiling a molecular vulnerability that could enhance treatment response.
Meta-analysis of ACE inhibitor–induced angioedema identifies novel risk locus
Authors: Carina M. Mathey, Carlo Maj, Niclas Eriksson, Kristi Krebs, Julia Westmeier, Friederike S. David, Maria Koromina, Annika B. Scheer, Nora Szabo, Bettina Wedi, Dorothea Wieczorek, Philipp M. Amann, Harald Löffler, Lukas Koch, Clemens Schöffl, Heinrich Dickel, Nomun Ganjuur, Thorsten Hornung, Timo Buhl, Jens Greve, Gerda Wurpts, Emel Aygören-Pürsün, Michael Steffens, Stefan Herms, Stefanie Heilmann-Heimbach, Per Hoffmann, Börge Schmidt, Laven Mavarani, Trine Andresen, Signe Bek Sørensen, Vibeke Andersen, Ulla Vogel, Mikael Landén, Cynthia M. Bulik, Anette Bygum, Patrik K.E. Magnusson, Christian von Buchwald, Pär Hallberg, Sisse Rye Ostrowski, Erik Sørensen, Ole B. Pedersen, Henrik Ullum, Christian Erikstrup, Henning Bundgaard, Lili Milani, Eva Rye Rasmussen, Mia Wadelius, Jonas Ghouse, Bernhardt Sachs, Markus M. Nöthen, Andreas J. Forstner
Journal: Journal of Allergy and Clinical Immunology (2024)

Angioedema is a rare but potentially life-threatening adverse drug reaction in patients receiving angiotensin-converting enzyme inhibitors (ACEis). Research suggests that susceptibility to ACEi-induced angioedema (ACEi-AE) involves both genetic and nongenetic risk factors. Genome- and exome-wide studies of ACEi-AE have identified the first genetic risk loci. However, understanding of the underlying pathophysiology remains limited.
Small-molecule CBP/p300 histone acetyltransferase inhibition mobilizes leukocytes from the bone marrow via the endocrine stress response
Authors: Nikolai P. Jaschke, Dorit Breining, Maura Hofmann, Sophie Pählig, Ulrike Baschant, Reinhard Oertel, Sofia Traikov, Tatyana Grinenko, Francesco Saettini, Andrea Biondi, Myrto Stylianou, Henrik Bringmann, Cuiling Zhang, Tomomi M. Yoshida, Heike Weidner, Wolfram C. Poller, Filip K. Swirski, Andy Göbel, Lorenz C. Hofbauer, Martina Rauner, Christoph Scheiermann, Andrew Wang, Tilman D. Rachner
Journal: Immunity (2024)

Mutations of the CBP/p300 histone acetyltransferase (HAT) domain can be linked to leukemic transformation in humans, suggestive of a checkpoint of leukocyte compartment sizes. Here, we examined the impact of reversible inhibition of this domain by the small-molecule A485. We found that A485 triggered acute and transient mobilization of leukocytes from the bone marrow into the blood. Leukocyte mobilization by A485 was equally potent as, but mechanistically distinct from, granulocyte colony-stimulating factor (G-CSF), which allowed for additive neutrophil mobilization when both compounds were combined. These effects were maintained in models of leukopenia and conferred augmented host defenses. Mechanistically, activation of the hypothalamus-pituitary-adrenal gland (HPA) axis by A485 relayed shifts in leukocyte distribution through corticotropin-releasing hormone receptor 1 (CRHR1) and adrenocorticotropic hormone (ACTH), but independently of glucocorticoids. Our findings identify a strategy for rapid expansion of the blood leukocyte compartment via a neuroendocrine loop, with implications for the treatment of human pathologies.
A role for the cerebellum in motor-triggered alleviation of anxiety
Authors: Xiao-Yang Zhang, Wen-Xia Wu, Li-Ping Shen, Miao-Jin Ji, Peng-Fei Zhao, Lei Yu, Jun Yin, Shu-Tao Xie, Yun-Yong Xie, Yang-Xun Zhang, Hong-Zhao Li, Qi-Peng Zhang, Chao Yan, Fei Wang, Chris I. De Zeeuw, Jian-Jun Wang, Jing-Ning Zhu
Journal: Neuron (2024)

Physical exercise is known to reduce anxiety, but the underlying brain mechanisms remain unclear. Here, we explore a hypothalamo-cerebello-amygdalar circuit that may mediate motor-dependent alleviation of anxiety. This three-neuron loop, in which the cerebellar dentate nucleus takes center stage, bridges the motor system with the emotional system. Subjecting animals to a constant rotarod engages glutamatergic cerebellar dentate neurons that drive PKCδ+ amygdalar neurons to elicit an anxiolytic effect. Moreover, challenging animals on an accelerated rather than a constant rotarod engages hypothalamic neurons that provide a superimposed anxiolytic effect via an orexinergic projection to the dentate neurons that activate the amygdala. Our findings reveal a cerebello-limbic pathway that may contribute to motor-triggered alleviation of anxiety and that may be optimally exploited during challenging physical exercise.
An atlas of cells in the human tonsil
Authors: Ramon Massoni-Badosa, Sergio Aguilar-Fernández, Juan C. Nieto, Paula Soler-Vila, Marc Elosua-Bayes, Domenica Marchese, Marta Kulis, Amaia Vilas-Zornoza, Marco Matteo Bühler, Sonal Rashmi, Clara Alsinet, Ginevra Caratù, Catia Moutinho, Sara Ruiz, Patricia Lorden, Giulia Lunazzi, Dolors Colomer, Gerard Frigola, Will Blevins, Lucia Romero-Rivero, Víctor Jiménez-Martínez, Anna Vidal, Judith Mateos-Jaimez, Alba Maiques-Diaz, Sara Ovejero, Jérôme Moreaux, Sara Palomino, David Gomez-Cabrero, Xabier Agirre, Marc A. Weniger, Hamish W. King, Lucy C. Garner, Federico Marini, Francisco Javier Cervera-Paz, Peter M. Baptista, Isabel Vilaseca, Cecilia Rosales, Silvia Ruiz-Gaspà, Benjamin Talks, Keval Sidhpura, Anna Pascual-Reguant, Anja E. Hauser, Muzlifah Haniffa, Felipe Prosper, Ralf Küppers, Ivo Glynne Gut, Elias Campo, José Ignacio Martin-Subero, Holger Heyn
Journal: Immunity (2024)

Palatine tonsils are secondary lymphoid organs (SLOs) representing the first line of immunological defense against inhaled or ingested pathogens. We generated an atlas of the human tonsil composed of >556,000 cells profiled across five different data modalities, including single-cell transcriptome, epigenome, proteome, and immune repertoire sequencing, as well as spatial transcriptomics. This census identified 121 cell types and states, defined developmental trajectories, and enabled an understanding of the functional units of the tonsil. Exemplarily, we stratified myeloid slan-like subtypes, established a BCL6 enhancer as locally active in follicle-associated T and B cells, and identified SIX5 as putative transcriptional regulator of plasma cell maturation. Analyses of a validation cohort confirmed the presence, annotation, and markers of tonsillar cell types and provided evidence of age-related compositional shifts. We demonstrate the value of this resource by annotating cells from B cell-derived mantle cell lymphomas, linking transcriptional heterogeneity to normal B cell differentiation states of the human tonsil.
Reversible, tunable epigenetic silencing of TCF1 generates flexibility in the T cell memory decision
Authors: Kathleen Abadie, Elisa C. Clark, Rajesh M. Valanparambil, Obinna Ukogu, Wei Yang, Riza M. Daza, Kenneth K.H. Ng, Jumana Fathima, Allan L. Wang, Judong Lee, Tahseen H. Nasti, Avinash Bhandoola, Armita Nourmohammad, Rafi Ahmed, Jay Shendure, Junyue Cao, Hao Yuan Kueh
Journal: Immunity (2024)

The immune system encodes information about the severity of a pathogenic threat in the quantity and type of memory cells it forms. This encoding emerges from lymphocyte decisions to maintain or lose self-renewal and memory potential during a challenge. By tracking CD8+ T cells at the single-cell and clonal lineage level using time-resolved transcriptomics, quantitative live imaging, and an acute infection model, we find that T cells will maintain or lose memory potential early after antigen recognition. However, following pathogen clearance, T cells may regain memory potential if initially lost. Mechanistically, this flexibility is implemented by a stochastic cis-epigenetic switch that tunably and reversibly silences the memory regulator, TCF1, in response to stimulation. Mathematical modeling shows how this flexibility allows memory T cell numbers to scale robustly with pathogen virulence and immune response magnitudes. We propose that flexibility and stochasticity in cellular decisions ensure optimal immune responses against diverse threats.
PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity
Authors: Emmanuelle Moraes Ribeiro, Kathy-Ann Secker, Ana-Maria Nitulescu, Rebekka Schairer, Hildegard Keppeler, Anton Wesle, Hannes Schmid, Anita Schmitt, Brigitte Neuber, Daniela Chmiest, Silvia Podavini, Melanie Märklin, Boris Klimovich, Michael Schmitt, Fulya Korkmaz, Claudia Lengerke, Corina Schneidawind, Dominik Schneidawind
Journal: Journal for ImmunoTherapy of Cancer (2024)

Relapse and graft-versus-host disease (GVHD) are the main causes of death after allogeneic hematopoietic cell transplantation (HCT). Preclinical murine models and clinical data suggest that invariant natural killer T (iNKT) cells prevent acute and chronic GVHD. In addition, iNKT cells are crucial for efficient immune responses against malignancies and contribute to reduced relapse rates after transplantation. Chimeric antigen receptors (CAR) redirect effector cells to cell surface antigens and enhance killing of target cells. With this study, we aimed to combine enhanced cytotoxicity of CD19-CAR-iNKT cells against lymphoma cells with their tolerogenic properties. iNKT cells were isolated from peripheral blood mononuclear cells and transduced with an anti-CD19-CAR retrovirus. After in vitro expansion, the functionality of CD19-CAR-iNKT cells was assessed by flow cytometry, image stream analysis and multiplex analysis in single-stimulation or repeated-stimulation assays. Moreover, the immunoregulatory properties of CD19-CAR-iNKT cells were analyzed in apoptosis assays and in mixed lymphocyte reactions. The effect of checkpoint inhibition through nivolumab was analyzed in these settings. In this study, we could show that the cytotoxicity of CD19-CAR-iNKT cells was mediated either through engagement of their CAR or their invariant T-cell receptor, which may circumvent loss of response through antigen escape. However, encounter of CD19-CAR-iNKT cells with their target induced a phenotype of exhaustion. Consequently, checkpoint inhibition increased cytokine release, cytotoxicity and survival of CD19-CAR-iNKT cells. Additionally, they showed robust suppression of alloreactive immune responses. In this work, we demonstrate that CAR-iNKT cells are a powerful cytotherapeutic option to prevent or treat relapse while potentially reducing the risk of GVHD after allogeneic HCT.
Hybrid Magnetic Resonance Positron Emission Tomography Is Associated With Cardiac-Related Outcomes in Cardiac Sarcoidosis
Authors: Maria Giovanna Trivieri, Philip M. Robson, Vittoria Vergani, Gina LaRocca, Angelica M. Romero-Daza, Ronan Abgral, Ana Devesa, Levi-Dan Azoulay, Nicolas A. Karakatsanis, Aditya Parikh, Christia Panagiota, Anna Palmisano, Louis DePalo, Helena L. Chang, Joseph H. Rothstein, Rima A. Fayad, Marc A. Miller, Valentin Fuster, Jagat Narula, Marc R. Dweck, Adam Morgenthau, Adam Jacobi, Maria Padilla, Jason C. Kovacic, Zahi A. Fayad
Journal: JACC. Cardiovascular imaging (2024)
Tricuspid Regurgitation and Clinical Outcomes in Heart Failure With Reduced Ejection Fraction
Authors: Marianna Adamo, Marco Metra, Brian L. Claggett, Zi Michael Miao, Rafael Diaz, G. Michael Felker, John J.V. McMurray, Scott D. Solomon, Tor Biering-Sørensen, Punag H. Divanji, Stephen B. Heitner, Stuart Kupfer, Fady I. Malik, John R. Teerlink
Journal: JACC Heart Failure (2024)
Ghosts of extinct apes: genomic insights into African hominid evolution
Authors: Robert A. Foley, Marta Mirazón Lahr
Journal: Trends in Ecology & Evolution (2024)

We are accustomed to regular announcements of new hominin fossils. There are now some 6000 hominin fossils, and up to 31 species. However, where are the announcements of African ape fossils? The answer is that there are almost none. Our knowledge of African ape evolution is based entirely on genomic analyses, which show that extant diversity is very young. This contrasts with the extensive and deep diversity of hominins known from fossils. Does this difference point to low and late diversification of ape lineages, or high rates of extinction? The comparative evolutionary dynamics of African hominids are central to interpreting living ape adaptations, as well as understanding the patterns of hominin evolution and the nature of the last common ancestor.
Complex architecture of cardiac muscle thick filaments revealed
Authors: Pradeep K. Luther, Steve B. Marston
Journal: Trends in Pharmacological Sciences (2024)

<h2>Abstract</h2> Muscle contraction is orchestrated by the well-understood thin filaments and the markedly complex thick filaments. Studies by Dutta et al. and Tamborrini et al., discussed here, have unravelled the structure of the mammalian heart thick filament in exquisite near-atomic detail and pave the way for understanding physiological modulation pathways and mutation-induced dysfunction and for designing potential drugs to modify defects.
Effectiveness of a comprehensive package based on electronic medication monitors at improving treatment outcomes among tuberculosis patients in Tibet: a multicentre randomised controlled trial
Authors: Xiaolin Wei, Joseph Paul Hicks, Zhitong Zhang, Victoria Haldane, Pande Pasang, Linhua Li, Tingting Yin, Bei Zhang, Yinlong Li, Qiuyu Pan, Xiaoqiu Liu, John Walley, Jun Hu
Journal: The Lancet (2024)
First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial
Authors: Hua Zhong, Shengjie Sun, Jianhua Chen, Ziping Wang, Yanqiu Zhao, Guojun Zhang, Gongyan Chen, Ming Zhou, Jianying Zhou, Yingying Du, Lin Wu, Zhi Xu, Xiaodong Mei, Weidong Zhang, Jingdong He, Jiuwei Cui, Zhihong Zhang, Hui Luo, Weiyou Liu, Meili Sun, Jingxun Wu, Yongchun Shen, Shucai Zhang, Nong Yang, Mengzhao Wang, Junguo Lu, Kai Li, Weirong Yao, Qian Sun, Hongmei Yue, Lin Wang, Sheng Ye, Bin Li, Xibin Zhuang, Yueyin Pan, Min Zhang, Yongqian Shu, Zhiyong He, Lei Pan, Yang Ling, Shengming Liu, Qi Zhang, Shunchang Jiao, Baohui Han
Journal: The Lancet Respiratory Medicine (2024)
Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein–Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial
Authors: Kris Michael Mahadeo, Robert Baiocchi, Amer Beitinjaneh, Sridhar Chaganti, Sylvain Choquet, Daan Dierickx, Rajani Dinavahi, Xinyuan Duan, Laurence Gamelin, Armin Ghobadi, Norma Guzman-Becerra, Manher Joshi, Aditi Mehta, Willis H Navarro, Sarah Nikiforow, Richard J O'Reilly, Ran Reshef, Fiona Ruiz, Tassja Spindler, Susan Prockop
Journal: The Lancet Oncology (2024)
APOE loss-of-function variants: Compatible with longevity and associated with resistance to Alzheimer’s disease pathology
Authors: Augustine Chemparathy, Yann Le Guen, Sunny Chen, Eun-Gyung Lee, Lesley Leong, John E. Gorzynski, Tanner D. Jensen, Alexis Ferrasse, Guangxue Xu, Hong Xiang, Michael E. Belloy, Nandita Kasireddy, Andrés Peña-Tauber, Kennedy Williams, Ilaria Stewart, Lia Talozzi, Thomas S. Wingo, James J. Lah, Suman Jayadev, Chadwick M. Hales, Elaine Peskind, Daniel D. Child, Sigrun Roeber, C. Dirk Keene, Le Cong, Euan A. Ashley, Chang-En Yu, Michael D. Greicius
Journal: Neuron (2024)
Efficacy and Safety of Glucagon-Like Peptide 1 Agonists in a Retrospective Study of Patients With Familial Partial Lipodystrophy
Authors: Maria C. Foss-Freitas, Salman Imam, Adam Neidert, Anabela Dill Gomes, David T. Broome, Elif A. Oral
Journal: Diabetes Care (2024)

Glucagon-like peptide 1 receptor agonists (GLP-1RA) are widely used for the management of diabetes mellitus (DM), but their efficacy in familial partial lipodystrophy (FPLD) is unknown. In this retrospective study, we evaluated the effect of GLP-1RA in patients with FPLD. We analyzed data, reported with SDs, from 14 patients with FPLD (aged 58 ± 12 years; 76.47% female) and 14 patients with type 2 DM (aged 58 ± 13 years; 71% female) before and 6 months after starting GLP-1RA. We observed reduction in weight (95 ± 23 to 91 ± 22 kg; P = 0.002), BMI (33 ± 6 to 31 ± 6 kg/m2; P = 0.001), HbA1c (8.2% ± 1.4% to 7.7% ± 1.4%; P = 0.02), and fasting glucose (186 ± 64 to 166 ± 53 mg/dL; P = 0.04) in patients with FPLD. The change in triglycerides after treatment was greater in the FPLD group compared with the DM group (P = 0.02). We noted acute pancreatitis in two case subjects with FPLD with longer therapy. Our study demonstrates the relative safety and effectiveness of GLP-1RA in patients with FPLD.
Associations of the ‘weekend warrior’ physical activity pattern with all-cause, cardiovascular disease and cancer mortality: the Mexico City Prospective Study
Authors: Gary O'Donovan, Fanny Petermann-Rocha, Gerson Ferrari, I-Min Lee, Mark Hamer, Emmanuel Stamatakis, Olga L Sarmiento, Agustín Ibáñez, Patricio Lopez-Jaramillo
Journal: British Journal of Sports Medicine (2024)

Objectives The objective was to investigate the benefits of the ‘weekend warrior’ physical activity pattern in Latin America, where many people take part in high levels of non-exercise physical activity. Methods Participants in the Mexico City Prospective Study were surveyed from 1998 to 2004 and resurveyed from 2015 to 2019. Those who exercised up to once or twice per week were termed weekend warriors. Those who exercised more often were termed regularly active. Analyses were adjusted for potential confounders. Results The main analysis included 26 006 deaths in 154 882 adults (67% female) aged 52±13 years followed for 18±4 years (mean±SD). Compared with those who reported no exercise, the HR (95% CI) was 0.88 (0.83 to 0.93) in the weekend warriors and 0.88 (0.84 to 0.91) in the regularly active. Similar results were observed for cardiovascular disease and cancer mortality, but associations were weaker. Stratified analyses showed that substantial reductions in all-cause mortality risk only occurred when the duration of exercise sessions was at least 30–60 min. The repeated-measures analysis included 843 deaths in 10 023 adults followed for 20±2 years. Compared with being inactive or becoming inactive, the HR was 0.86 (95% CI 0.65 to 1.12) when being a weekend warrior or becoming a weekend warrior and 0.85 (95% CI 0.70 to 1.03) when being regularly active or becoming regularly active. Conclusions This is the first prospective study to investigate the benefits of the weekend warrior physical activity pattern in Latin America. The results suggest that even busy adults could benefit from taking part in one or two sessions of exercise per week.